A Study of Itraconazole in the Prevention of Histoplasmosis, a Fungal Infection, in HIV-Infected Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To assess the safety and efficacy of itraconazole versus placebo for prevention of
histoplasmosis in HIV-infected patients with CD4 counts < 150 cells/mm3 who reside where
histoplasmosis is endemic. To assess the safety and efficacy of itraconazole for preventing
other debilitating fungal infections, such as cryptococcosis, aspergillosis, recalcitrant
oropharyngeal or vaginal candidiasis, and recurrent esophageal candidiasis.